Suppr超能文献

单纯放疗的宫颈癌患者中,总治疗时间和放射生物学参数对生物等效剂量的影响。

Influence of overall treatment time and radiobiological parameters on biologically effective doses in cervical cancer patients treated with radiation therapy alone.

作者信息

Gasinska Anna, Fowler Jack F, Lind Bengt K, Urbanski Krzysztof

机构信息

Laboratory of Radiation Biology, Department of Radiation Therapy, Centre of Oncology, Krakow, Poland.

出版信息

Acta Oncol. 2004;43(7):657-66. doi: 10.1080/02841860410018511.

Abstract

The aim of the study was to examine the influence of overall treatment time (OTT) on the value of calculated biological effective doses (BEDs) for different biological variables. These variables were: tumour proliferation rate, different cell radiosensitivity (alpha=0.2, 0.3, and 0.4 /Gy), and different start time for repopulation (Tk=21, 28, and 35 days). Also the influence of age (</= 50 years >), Hb level (</= 116 g/l>), tumor proliferation rate (bromodeoxyuridine labelling index; BrdUrdLI), and DNA ploidy on survival after shorter (</= 60 days) or longer (>60 days) OTT was investigated. The study included 229 patients with cervix carcinoma treated entirely by standard radiotherapy (RT) (external beam RT plus low-medium dose-rate (LDR/MDR) brachytherapy (BT) at the Center of Oncology in Krakow. The linear quadratic equation was used to calculate BED, which is proportional to log cell kill. BEDs 10 (for tumours) were calculated with consideration of OTT for each patient and tumour proliferation rate (standardized potential doubling time; standardized Tpot) based on BrdUrdLI assessed on biopsy material before RT. Median OTT was 90 days (range 30-210). The mean calculated total BED for point A for tumour and 'early reactions' was equal to 103.0 Gy10. The longest median survival time--52 months--was seen for patients treated with OTT </= 60 days. If OTT exceeded 90 days to more than 120 days, loss in BED10 for relatively radiosensitive tumours (alpha=0.3-0.4/Gy and Tk=28 days) was equal to 0.37-0.26 Gy/day. However, for radioresistant tumours (alpha=0.2/Gy) it was 0.6 Gy/day. For fast proliferating tumours (BrdUrdLI >8.8%) BED loss was 1.4 Gy/day and for slowly proliferating tumours (BrdUrdLI </= 8.8%) it was 0.2 Gy/day. Assuming shorter (21 days) or longer (35 days) periods for Tk and relatively radiosensitive tumours similar BED loss of 0.38 Gy/day was observed. Kaplan-Meier analysis revealed that OTT </= 60 days was a significant prognostic factor for overall survival (OS) (p=0.019), disease-free survival (DFS) (p=0.0173), and local control (LC) (p=0.011). BED10 had significant influence on survival (p=0.047). Cox multivariate analysis revealed that for OTT shorter than 60 days the only favourable significant parameters were: age >50 years (p=0.003) and high Hb level (>116 g/l) (p=0.041). For longer treatments (OTT >60 days) the unfavourable parameters were: age </= 50 years (p=0.037), BrdUrdLI </= 8.8% (p=0.003), tumour aneuploidy (p=0.043), and BED10 </= 103 Gy (p=0.017). The examined tumour biological parameters should be taken into account for RT and provide a basis for adjuvant RT.

摘要

本研究的目的是探讨总治疗时间(OTT)对不同生物学变量计算所得生物等效剂量(BED)值的影响。这些变量包括:肿瘤增殖率、不同的细胞放射敏感性(α = 0.2、0.3和0.4 /Gy)以及不同的再增殖起始时间(Tk = 21、28和35天)。此外,还研究了年龄(≤50岁或>50岁)、血红蛋白水平(≤116 g/l或>116 g/l)、肿瘤增殖率(溴脱氧尿苷标记指数;BrdUrdLI)和DNA倍性对较短(≤60天)或较长(>60天)OTT后的生存率的影响。该研究纳入了229例宫颈癌患者,均在克拉科夫肿瘤中心接受了单纯标准放疗(RT)(外照射放疗加低 - 中剂量率(LDR/MDR)近距离放疗(BT))。采用线性二次方程计算BED,其与对数细胞杀灭成正比。根据放疗前活检材料评估的BrdUrdLI,考虑每位患者的OTT和肿瘤增殖率(标准化潜在倍增时间;标准化Tpot),计算肿瘤的BED10。OTT的中位数为90天(范围30 - 210天)。肿瘤和“早期反应”的A点计算所得总BED平均值等于103.0 Gy10。OTT≤60天的患者观察到最长的中位生存时间——52个月。如果OTT超过90天至120天以上,相对放射敏感的肿瘤(α = 0.3 - 0.4 /Gy且Tk = 28天)的BED10损失等于0.37 - 0.26 Gy/天。然而,对于放射抗拒的肿瘤(α = 0.2 /Gy),损失为0.6 Gy/天。对于快速增殖的肿瘤(BrdUrdLI>8.8%),BED损失为1.4 Gy/天,对于缓慢增殖的肿瘤(BrdUrdLI≤8.8%),损失为0.2 Gy/天。假设Tk为较短(21天)或较长(35天)且肿瘤相对放射敏感时,观察到类似的BED损失为0.38 Gy/天。Kaplan - Meier分析显示,OTT≤60天是总生存(OS)(p = 0.019)、无病生存(DFS)(p = 0.0173)和局部控制(LC)(p = 0.011)的显著预后因素。BED10对生存有显著影响(p = 0.047)。Cox多因素分析显示,对于OTT短于60天,仅有的有利显著参数为:年龄>50岁(p = 0.003)和高血红蛋白水平(>116 g/l)(p = 0.041)。对于较长疗程(OTT>60天),不利参数为:年龄≤50岁(p = 0.037)、BrdUrdLI≤8.8%(p = 0.003)、肿瘤非整倍体(p = 0.043)和BED10≤103 Gy(p = 0.017)。放疗时应考虑所检测的肿瘤生物学参数,并为辅助放疗提供依据。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验